[go: up one dir, main page]

WO2007023182A1 - Delta and epsilon crystal forms of imatinib mesylate - Google Patents

Delta and epsilon crystal forms of imatinib mesylate Download PDF

Info

Publication number
WO2007023182A1
WO2007023182A1 PCT/EP2006/065662 EP2006065662W WO2007023182A1 WO 2007023182 A1 WO2007023182 A1 WO 2007023182A1 EP 2006065662 W EP2006065662 W EP 2006065662W WO 2007023182 A1 WO2007023182 A1 WO 2007023182A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystalline form
compound
formula
acid addition
addition salt
Prior art date
Application number
PCT/EP2006/065662
Other languages
French (fr)
Inventor
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37192362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007023182(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CN200680030515XA priority Critical patent/CN101243066B/en
Priority to AU2006283842A priority patent/AU2006283842B2/en
Priority to JP2008527470A priority patent/JP2009506014A/en
Priority to CA002620835A priority patent/CA2620835A1/en
Priority to MX2008002541A priority patent/MX2008002541A/en
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to BRPI0615383-6A priority patent/BRPI0615383A2/en
Priority to US12/064,637 priority patent/US7879860B2/en
Priority to EP06792999A priority patent/EP1922314A1/en
Publication of WO2007023182A1 publication Critical patent/WO2007023182A1/en
Priority to IL189353A priority patent/IL189353A/en
Priority to NO20081482A priority patent/NO20081482L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

  • the invention relates to particular crystal forms of the methanesulfonic acid addition salt of 4- (4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]- benzamide (the compound of formula I, see below), certain processes for their preparation, pharmaceutical compositions containing these crystal forms, and their use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans.
  • lmatinib mesylate also known as lmatinib mesylate or STI571 , the alpha and the beta crystal form thereof, as well as its pharmaceutical use are described in US 6,894,051.
  • lmatinib mesylate is the active ingredient of the drug Gleevec® (Glivec®) which is an approved medicament for the treatment of Chronic Myeloid Leukemia (CML) and gastrointestinal stromal tumors (GIST).
  • Glivec® is an approved medicament for the treatment of Chronic Myeloid Leukemia (CML) and gastrointestinal stromal tumors (GIST).
  • Glivec® is an approved medicament for the treatment of Chronic Myeloid Leukemia (CML) and gastrointestinal stromal tumors (GIST).
  • Glivec® is an approved medicament for the treatment of Chronic Myeloid Leukemia (CML) and gastrointestinal stromal tumors (GIST).
  • Glivec® is an approved medicament for the treatment of Chronic Myeloid Leukemia (CML)
  • the invention relates especially to essentially pure crystal forms, preferably those which are referred to hereinafter as the ⁇ -crystal and the ⁇ -crystal form form, of the methanesulfonic acid addition salt of lmatinib of formula I,
  • Fig. 1 shows the X-ray diffraction diagram of the ⁇ -crystal form of the methanesulfonic acid addition salt of a compound of formula I.
  • the angle of refraction 2theta is plotted on the horizontal axis (x-axis) and the relative line intensity (background-corrected peak intensity) on the vertical (y-axis).
  • the strongest line in the X-ray diffraction diagram is observed at an angle of refraction 2theta of 19.8° having a relative line intensity of 100 %. More broadly, the ⁇ -crystal form is characterized by refractions at angles of refraction 2theta of 19.2° (70), 19.4° (51 ), 19.8° (100), 20.3° (60), 20.7° (52), 20.9° (65) and 21.1 ° (69).
  • the ⁇ -crystal form of the methanesulfonic acid addition salt of a compound of formula I is also characterized by lines in the X-ray diffraction diagram observed at an angle of refraction 2theta of 7.8, 8.3 and 9.0.
  • Fig. 2 shows the X-ray diffraction diagram of the ⁇ -crystal form of the methanesulfonic acid addition salt of a compound of formula I.
  • the angle of refraction 2theta is plotted on the horizontal axis (x-axis) and the relative line intensity (background-corrected peak intensity) on the vertical (y-axis).
  • the strongest line in the X-ray diffraction diagram is observed at an angle of refraction 2theta of 20.7° having a relative line intensity of 100 %.
  • the ⁇ -crystal form is characterized by refractions at angles of refraction 2theta of (a) 17.0°, said peak having a relative line intensity of 99, (b) 18.5°, said peak having a relative line intensity of 80, (c) 19.6°, said peak having a relative line intensity of 78 and (d) 20.7°, said peak having a relative line intensity of 100.
  • the ⁇ -crystal form is characterized by refractions at angles of refraction 2theta of 13.9° (58), 17.0° (99), 17.9° (59), 18.5° (80), 19.6° (78), 20.7° (100) and 24.1 ° (62).
  • the ⁇ -crystal form of the methanesulfonic acid addition salt of a compound of formula I is also characterized by a line in the X-ray diffraction diagram observed at an angle of refraction 2theta of 9.4.
  • essentially pure is understood in the context of the present invention to mean especially that at least 90, preferably at least 95, and most preferably at least 99 per cent by weight of the crystals of an acid addition salt of formula I are present in the specified crystal form according to the invention, especially the ⁇ -crystal form or the ⁇ -crystal form.
  • the term "essentially” means that at least the major lines of the diagram depicted in Fig. 1 , i.e. those having a relative line intensity of more than 20%, especially more than 30 %, as compared to the most intense line in the diagram, have to be present.
  • the term "essentially” means that at least the major lines of the diagram depicted in Fig. 2, i.e. those having a relative line intensity of more than 20%, especially more than 30 %, as compared to the most intense line in the diagram, have to be present.
  • the invention expressly relates also to those forms of the methanesulfonic acid addition salt of a compound of formula I in which crystals of the ⁇ -crystal form and/or the ⁇ -crystal form according to the invention are present in essentially pure form along with other crystal forms, in particular the ⁇ -crystal form, the ⁇ -crystal form, the H1-crystal form and/or the amorphous form of the lmatinib mesylate.
  • the essentially pure methanesulfonic acid addition salt of a compound of formula I in the ⁇ -crystal form shows the X-ray diffraction diagram indicated in Fig. 1.
  • the ⁇ -crystal form of the methanesulfonic acid addition salt of a compound of formula I which shows an X-ray diffraction diagram of the type shown in Fig. 1 , in which the relative peak intensities of each peak do not deviate by more than 10% from the relative peak intensities in the diagram shown in Fig. 1 , especially an X-ray diffraction diagram identical to that shown in Fig. 1.
  • the essentially pure methanesulfonic acid addition salt of a compound of formula I in the ⁇ -crystal form shows the X-ray diffraction diagram indicated in Fig. 2.
  • One utility of the ⁇ -crystal form and the ⁇ -crystal form of the methanesulfonic acid addition salt of a compound of formula I is the use as an intermediate for the preparation of a distinct crystal form of the methanesulfonic acid addition salt of a compound of formula I, especially the ⁇ -crystal form.
  • the (preferably essentially pure) ⁇ -crystal form is obtainable by a) digesting the ⁇ -crystal form of the methanesulfonic acid addition salt of a compound of formula I with a suitable polar solvent, especially an alcohol, most especially methanol, or also a ketone (especially in a mixture with water, for example water/acetone), typically acetone, a N,N-di-lower alkyl-lower alkanecarboxamide, typically N,N-dimethylformamide or - acetamide, or a hydrophilic ether, typically dioxane, preferably in the presence of some water, or mixtures thereof, in suspension at a suitable temperature, preferably a temperature between 20 and 50 0 C, for example at about 25°C, or b) dissolving the ⁇ -crystal form of the methanesulfonic acid addition salt of a compound of formula I with a suitable polar solvent, such as especially an alcohol, typically methanol or ethanol,
  • distinct crystal forms are prone to incorporate distinct impurities upon crystallization, i.e. an impurity incorporated in crystal form ⁇ is not necessarily also incorporated in the crystal form ⁇ op in the crystal form ⁇ .
  • distinct crystal forms display different physical properties such as melting points, hygroscopicities, solubilities, flow properties or thermodynamic stabilities, and, hence, distinct crystal forms allow the choice of the most suitable form for a certain use or aspect, e.g. the use as an intermediate in the process of drug manufacture or in distinct administration forms like tablets, capsules, ointments or solutions.
  • the ⁇ -crystal form and the ⁇ -crystal form of the methanesulfonic acid addition salt of a compound of formula I possesses valuable pharmacological properties and may, for example, be used as an anti-tumour agent or as an agent to treat restenosis.
  • the present invention relates especially to the ⁇ -crystal form of the methanesulfonic acid addition salt of a compound of formula I in the treatment of one of the said diseases mentioned herein or in the preparation of a pharmacological agent for the treatment thereof.
  • the present invention relates especially to the ⁇ -crystal form of the methanesulfonic acid addition salt of a compound of formula I in the treatment of one of the said diseases mentioned herein or in the preparation of a pharmacological agent for the treatment thereof.
  • the antiproliferative, especially anti-tumour, activity of the methanesulfonic acid addition salt of a compound of formula I in vivo is, for example, described for the treatment of abl- dependent tumours in Nature Med. 2, 561-6 (1996).
  • the invention relates also to a method for the treatment of warm-blooded animals suffering from said diseases, especially leukemia, wherein a quantity of the ⁇ -crystal form or of the ⁇ - crystal form of the methanesulfonic acid addition salt of a compound of formula I which is effective against the disease concerned, especially a quantity with antiproliferative efficacy, is administered to warm-blooded animals in need of such treatment.
  • the invention relates moreover to the use of the ⁇ -crystal form or of the ⁇ -crystal form of the methanesulfonic acid addition salt of a compound of formula I for the preparation of pharmaceutical compositions for use in treating the human or animal body, especially for the treatment of tumours, such as gliomas or prostate tumours.
  • the present invention relates to the use in of the ⁇ -crystal form or of the ⁇ -crystal form of the methanesulfonic acid addition salt of a compound of formula I in the treatment of one of the disorders listed below: 1. metastatic, inoperable GIST, 2. advanced chronic myeloid leukemia,
  • ALL Philadelphia chromosome-positive acute lymphocytic leukemia
  • glioblastoma multiforme preferably in combination with hydroxyurea
  • DFSP dermatofibrosarcoma protuberans
  • HES hypereosinophilic Sindrome
  • CMML chronic myelomonocytic leucemia
  • effective doses for example daily doses of about 50-2500 mg, preferably 100-1000 mg, especially 250-800 mg, of lmatinib mesylate having the ⁇ -crystal form or the ⁇ -crystal form are administered to warm-blooded animals of about 70 kg bodyweight.
  • daily dosages of 400 mg or 600 mg are administered orally once daily, preferably together with a meal and a large glass of water (about 200 mL).
  • 800 mg daily dosages are preferably administered in the form of 400 mg dosages twice daily together with food.
  • the ⁇ -crystal form and the ⁇ -crystal form described herein can be utilized to prepare stable pharmaceutical dosage forms.
  • the invention relates also to pharmaceutical preparations which contain an amount, especially an effective amount for prevention or treatment of one of the diseases mentioned herein, of the methanesulfonic acid addition salt of a compound of formula I in the ⁇ -crystal form or the ⁇ -crystal form, together with pharmaceutically acceptable carriers which are suitable for topical, enteral, for example oral or rectal, or parenteral administration and may be inorganic or organic and solid or liquid.
  • diluents for example lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and/or glycerin
  • lubricants for example silica, talc, stearic acid, or salts thereof, typically magnesium or calcium stearate, and/or polyethylene glycol, are used for oral administration.
  • Tablets may likewise contain binders, for example magnesium aluminium silicate, starches, typically corn, wheat or rice starch, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and, if so desired, disintegrants, for example starches, agar, alginic acid, or a salt thereof, typically sodium alginate, and/or effervescent mixtures, or adsorbents, colouring agents, flavours, and sweetening agents.
  • binders for example magnesium aluminium silicate, starches, typically corn, wheat or rice starch, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and, if so desired, disintegrants, for example starches, agar, alginic acid, or a salt thereof, typically sodium alginate, and/or effervescent mixtures, or adsorbents, colouring agents, flavours, and sweetening agents.
  • Such solutions are preferably isotonic aqueous solutions or suspensions, these possibly being prepared before use, for example in the case of lyophilised preparations containing the active substance either alone or together with a carrier, for example mannitol.
  • the pharmaceutical substances may be sterilised and/or may contain excipients, for example preservatives, stabilisers, wetting agents and/or emulsifiers, solubilisers, salts for the regulation of osmotic pressure, and/or buffers.
  • the present pharmaceutical preparations which, if so desired, may contain further pharmacologically active substances, are prepared in a manner known per se, for example by means of conventional mixing, granulating, coating, dissolving or lyophilising processes, and contain from about 1 % to 100%, especially from about 1 % to about 20%, of the active substance or substances.
  • the tablet or capsule contains 50 mg 100 mg of the of the methanesulfonic acid addition salt of a compound of formula I in the ⁇ -crystal form, optionally together with pharmaceutically acceptable carriers.
  • the capsule is a hard gelatine capsule containing a dry powder blend.
  • the capsule shell preferably contains gelatine and titanium dioxide as well as red iron oxide.
  • the ratio of weight of capsule fill to capsule shell is preferably between about 100:25 and 100:50, more preferably between 100:30 and 100:40.
  • a film coated tablet comprising 100 mg, 400 mg or 800 mg drug substance together with inactive excepients selected from colloidal anhydrous silica, polyvinylpyrrolidone, magnesium stearate and microcrystalline cellulose.
  • Example 1 Preparation of crystalline form delta of lmatinib mesylate using acetone and methanol
  • lmatinib mesylate About 500mg of lmatinib mesylate is first dissolved in about 100ml of water. A micro reactor is charged with about 50 ⁇ l of this aqueous solution of lmatinib mesylate. The solution is flushed with nitrogen at room temperature to dry the solution. The dry precipitate is re- suspended with about 125 ⁇ l amounts of each, acetone and methanol. The suspension is aged at about 45-55°C for about 2hrs. The solution is then allowed to evaporate at 45°C to 55°C under a stream of nitrogen.
  • Example 2 Tablets with lmatinib mesylate, ⁇ -crvstal form
  • Tablets containing 100 mg of the active substance named in the title are usually prepared in the following composition:
  • the active substance is mixed with carrier materials and compressed on a tableting machine (Korsch EKO, punch diameter 10 mm).
  • Avicel is microcrystalline cellulose (FMC, Philadelphia, USA).
  • PVPPXL is polyvinylpyrrolidone, cross-linked (BASF, Germany). Aerosil is silicon dioxide (Degussa, Germany).
  • Example 3 Capsules with lmatinib mesylate, ⁇ -crvstal form
  • Capsules containing 100 mg of the compound named in the title as active substance are usually prepared in the following composition:
  • the capsules are prepared by mixing the components and filling the mixture into hard gelatin capsules, size 1.
  • Example 4 Preparation of crystalline form epsilon of lmatinib mesylate using ethyl acetate and ethanol
  • lmatinib mesylate drug substance is first dissolved in about 100ml of water.
  • a micro reactor is charged with about 50 ⁇ l of this aqueous solution of lmatinib mesylate.
  • the solution is flushed with nitrogen at room temperature to dry the solution.
  • the dry precipitate is resuspended with about 125 ⁇ l amounts of each, ethyl acetate and 95% ethanol.
  • the suspension is aged at about 45-55°C for about 2hrs.
  • the solution is then allowed to evaporate at 45°C to 55°C under a stream of nitrogen.
  • Example 5 Tablets with lmatinib mesylate, ⁇ -crvstal form
  • Tablets containing 100 mg of the active substance named in the title are usually prepared in the following composition:
  • the active substance is mixed with carrier materials and compressed on a tableting machine (Korsch EKO, punch diameter 10 mm).
  • Avicel is microcrystalline cellulose (FMC, Philadelphia, USA).
  • PVPPXL is polyvinylpolypyrrolidone, cross-linked (BASF, Germany). Aerosil is silicon dioxide (Degussa, Germany).
  • Example 6 Capsules with lmatinib mesylate, ⁇ -crvstal form
  • Capsules containing 100 mg of the compound named in the title as active substance are usually prepared in the following composition:
  • the capsules are prepared by mixing the components and filling the mixture into hard gelatin capsules, size 1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to the delta and epsilon crystal form of the methanesulfonic acidaddition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide (the compound of formula I, see below), certain processes for their preparation, pharmaceutical compositions containing these crystal forms, and their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, especially humans.

Description

Delta and epsilon crystal forms of lmatinib mesylate
The invention relates to particular crystal forms of the methanesulfonic acid addition salt of 4- (4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]- benzamide (the compound of formula I, see below), certain processes for their preparation, pharmaceutical compositions containing these crystal forms, and their use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans.
Background to the invention
The preparation of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin- 2-ylamino)phenyl]-benzamide, also known as lmatinib, and its use, especially as an anti- tumour agent, are described in EP-A-O 564 409, which was published on 6 October 1993, and in equivalent applications in numerous other countries. The compound is exemplified in these publications only in free form (not as a salt).
4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]- benzamide mesylate, also known as lmatinib mesylate or STI571 , the alpha and the beta crystal form thereof, as well as its pharmaceutical use are described in US 6,894,051. lmatinib mesylate is the active ingredient of the drug Gleevec® (Glivec®) which is an approved medicament for the treatment of Chronic Myeloid Leukemia (CML) and gastrointestinal stromal tumors (GIST). Another polymorph of lmatinib mesylate, the so- called H1-form, is described in WO2004/106326.
It has now been surprisingly found that under certain conditions new crystal forms of the methanesulfonate salt may be found, which are described hereinafter as δ-crystal form and ε- crystal form, and which have advantageous utilities and properties. Detailed description of the invention
The invention is described in more detail in the following with the help of drawings and other aids.
The invention relates especially to essentially pure crystal forms, preferably those which are referred to hereinafter as the δ-crystal and the ε-crystal form form, of the methanesulfonic acid addition salt of lmatinib of formula I,
Figure imgf000003_0001
Description of the drawings
Fig. 1 shows the X-ray diffraction diagram of the δ-crystal form of the methanesulfonic acid addition salt of a compound of formula I. In the X-ray diagram, the angle of refraction 2theta is plotted on the horizontal axis (x-axis) and the relative line intensity (background-corrected peak intensity) on the vertical (y-axis). X-ray powder diffraction patterns are measured on a Bruker D8 with Cu Ka radiation source (Kα1 radiation, wavelength λ = 1.54060 Angstrom). The optical density of the lines on the film is proportional to the light intensity. The film is scanned in using a line scanner. The strongest line in the X-ray diffraction diagram is observed at an angle of refraction 2theta of 19.8° having a relative line intensity of 100 %. More broadly, the δ-crystal form is characterized by refractions at angles of refraction 2theta of 19.2° (70), 19.4° (51 ), 19.8° (100), 20.3° (60), 20.7° (52), 20.9° (65) and 21.1 ° (69). In essentially pure material of the δ-crystal form of the methanesulfonic acid addition salt of a compound of formula I, lines can be observed at angles of refraction 2theta 16.5° (44), 16.8° (44), 19.2° (70), 19.4° (51 ), 19.8° (100), 20.3° (60), 20.7° (52), 20.9° (65), 21.1 ° (69) and 22.7° (41 ). Depending on the instruments used for X-ray diffraction analysis and the purity of the analyzed material containing the δ-crystal form of the methanesulfonic acid addition salt of a compound of formula I, it should be possible to observe lines having a relative line intensity of 30 % or more at the following angles of refraction 2theta (relative line intensities given in parentheses): 2.2° (35), 13.0° (39), 14.4° (36), 16.0° (34), 16.5° (44), 16.8° (44), 19.2° (70), 19.4° (51 ), 19.8° (100), 20.3° (60), 20.7° (52), 20.9° (65), 21.1 ° (69), 21.5° (36), 22.7° (41 ), 23.7° (33), 24.4° (37), 24.7° (33), 25.3° (31 ), 25.6° (34), 26.3° (39) and 28.1 ° (34).
The δ-crystal form of the methanesulfonic acid addition salt of a compound of formula I is also characterized by lines in the X-ray diffraction diagram observed at an angle of refraction 2theta of 7.8, 8.3 and 9.0.
Fig. 2 shows the X-ray diffraction diagram of the ε-crystal form of the methanesulfonic acid addition salt of a compound of formula I. In the X-ray diagram, the angle of refraction 2theta is plotted on the horizontal axis (x-axis) and the relative line intensity (background-corrected peak intensity) on the vertical (y-axis). X-ray powder diffraction patterns are measured on a Bruker D8 with Cu Ka radiation source (Kα1 radiation, wavelength λ = 1.54060 Angstrom). The optical density of the lines on the film is proportional to the light intensity. The film is scanned in using a line scanner. The strongest line in the X-ray diffraction diagram is observed at an angle of refraction 2theta of 20.7° having a relative line intensity of 100 %. The ε-crystal form is characterized by refractions at angles of refraction 2theta of (a) 17.0°, said peak having a relative line intensity of 99, (b) 18.5°, said peak having a relative line intensity of 80, (c) 19.6°, said peak having a relative line intensity of 78 and (d) 20.7°, said peak having a relative line intensity of 100. More broadly, the ε-crystal form is characterized by refractions at angles of refraction 2theta of 13.9° (58), 17.0° (99), 17.9° (59), 18.5° (80), 19.6° (78), 20.7° (100) and 24.1 ° (62).
In essentially pure material of the ε-crystal form of the methanesulfonic acid addition salt of a compound of formula I, lines can be observed at angles of refraction 2theta 12.7° (48), 13.9° (58), 17.0° (99), 17.9° (59), 18.5° (80), 19.6° (78), 20.7° (100), 21.4° (40), 23.6° (49), 24.1 ° (62) and 28.2° (45). Depending on the instruments used for X-ray diffraction analysis and the purity of the analyzed material containing the ε-crystal form of the methanesulfonic acid addition salt of a compound of formula I, it should be possible to observe lines having a relative line intensity of 30 % or more at the following angles of refraction 2theta (relative line intensities given in parentheses): 9.4° (35), 11.9° (36), 12.7° (48), 13.3° (35), 13.9° (58), 15.0° (37), 15.3° (32), 17.0° (99), 17.9° (59), 18.5° (80), 19.0° (34), 19.6° (78), 20.7° (100), 21.4° (40), 23.6° (49), 24.1 ° (62) and 28.2° (45).
The ε-crystal form of the methanesulfonic acid addition salt of a compound of formula I is also characterized by a line in the X-ray diffraction diagram observed at an angle of refraction 2theta of 9.4.
The term "essentially pure" is understood in the context of the present invention to mean especially that at least 90, preferably at least 95, and most preferably at least 99 per cent by weight of the crystals of an acid addition salt of formula I are present in the specified crystal form according to the invention, especially the δ-crystal form or the ε-crystal form.
In the context with stating that the δ-crystal form of the methanesulfonic acid addition salt of a compound of formula I exhibits an X-ray diffraction diagram essentially as in Fig. 1 , the term "essentially" means that at least the major lines of the diagram depicted in Fig. 1 , i.e. those having a relative line intensity of more than 20%, especially more than 30 %, as compared to the most intense line in the diagram, have to be present.
In the context with stating that the ε-crystal form of the methanesulfonic acid addition salt of a compound of formula I exhibits an X-ray diffraction diagram essentially as in Fig. 2, the term "essentially" means that at least the major lines of the diagram depicted in Fig. 2, i.e. those having a relative line intensity of more than 20%, especially more than 30 %, as compared to the most intense line in the diagram, have to be present.
The invention expressly relates also to those forms of the methanesulfonic acid addition salt of a compound of formula I in which crystals of the δ-crystal form and/or the ε-crystal form according to the invention are present in essentially pure form along with other crystal forms, in particular the α-crystal form, the β-crystal form, the H1-crystal form and/or the amorphous form of the lmatinib mesylate. Preferred, however, are the δ-crystal form and the ε-crystal form in essentially pure form, respectively.
In one preferred embodiment, the essentially pure methanesulfonic acid addition salt of a compound of formula I in the δ-crystal form shows the X-ray diffraction diagram indicated in Fig. 1. High preference is also given for the δ-crystal form of the methanesulfonic acid addition salt of a compound of formula I which shows an X-ray diffraction diagram of the type shown in Fig. 1 , in which the relative peak intensities of each peak do not deviate by more than 10% from the relative peak intensities in the diagram shown in Fig. 1 , especially an X-ray diffraction diagram identical to that shown in Fig. 1.
In another preferred embodiment, the essentially pure methanesulfonic acid addition salt of a compound of formula I in the ε-crystal form shows the X-ray diffraction diagram indicated in Fig. 2.
High preference is furthermore given for the ε-crystal form of the methanesulfonic acid addition salt of a compound of formula I which shows an X-ray diffraction diagram of the type shown in Fig. 2, in which the relative peak intensities of each peak do not deviate by more than 10% from the relative peak intensities in the diagram shown in Fig. 2, especially an X- ray diffraction diagram identical to that shown in Fig. 2.
Of particularly high preference are the δ-crystal form and for the ε-crystal form of the methanesulfonic acid addition salt of a compound of formula I obtainable as described in the Examples.
One utility of the δ-crystal form and the ε-crystal form of the methanesulfonic acid addition salt of a compound of formula I is the use as an intermediate for the preparation of a distinct crystal form of the methanesulfonic acid addition salt of a compound of formula I, especially the β-crystal form. The (preferably essentially pure) β-crystal form is obtainable by a) digesting the δ-crystal form of the methanesulfonic acid addition salt of a compound of formula I with a suitable polar solvent, especially an alcohol, most especially methanol, or also a ketone (especially in a mixture with water, for example water/acetone), typically acetone, a N,N-di-lower alkyl-lower alkanecarboxamide, typically N,N-dimethylformamide or - acetamide, or a hydrophilic ether, typically dioxane, preferably in the presence of some water, or mixtures thereof, in suspension at a suitable temperature, preferably a temperature between 20 and 500C, for example at about 25°C, or b) dissolving the δ-crystal form of the methanesulfonic acid addition salt of a compound of formula I with a suitable polar solvent, such as especially an alcohol, typically methanol or ethanol, a ketone (especially in a mixture with water, for example water/acetone) typically acetone, a N,N-di-lower alkyl-lower alkanecarboxamide, typically N,N-dimethylformamide or - acetamide, or a hydrophilic ether, typically dioxane, or mixtures thereof, preferably in the presence of some water, at a suitable temperature, especially after heating the solvent, or while warming during the dissolution process, in both cases preferably to 25°C up to the reflux temperature of the reaction mixture, and then initiating crystallisation by adding a small amount of the β-crystal form as seed crystal at a suitable temperature, for example between 0 and 700C, preferably between 20 and 700C, or c) digesting the ε-crystal form of the methanesulfonic acid addition salt of a compound of formula I with a suitable polar solvent, especially an alcohol, most especially methanol, or also a ketone (especially in a mixture with water, for example water/acetone), typically acetone, a N,N-di-lower alkyl-lower alkanecarboxamide, typically N,N-dimethylformamide or - acetamide, or a hydrophilic ether, typically dioxane, preferably in the presence of some water, or mixtures thereof, in suspension at a suitable temperature, preferably a temperature between 20 and 50°C, for example at about 25°C, or d) dissolving the ε-crystal form of the methanesulfonic acid addition salt of a compound of formula I with a suitable polar solvent, such as especially an alcohol, typically methanol or ethanol, a ketone (especially in a mixture with water, for example water/acetone) typically acetone, a N,N-di-lower alkyl-lower alkanecarboxamide, typically N,N-dimethylformamide or - acetamide, or a hydrophilic ether, typically dioxane, or mixtures thereof, preferably in the presence of some water, at a suitable temperature, especially after heating the solvent, or while warming during the dissolution process, in both cases preferably to 25°C up to the reflux temperature of the reaction mixture, and then initiating crystallisation by adding a small amount of the β-crystal form as seed crystal at a suitable temperature, for example between 0 and 700C, preferably between 20 and 700C.
One of the advantages of having access to different crystal forms of the compound of formula I is the fact that distinct crystal forms are prone to incorporate distinct impurities upon crystallization, i.e. an impurity incorporated in crystal form β is not necessarily also incorporated in the crystal form δ op in the crystal form ε. With other words, preparing consecutively distinct crystal forms of the same material increases the purity of the finally obtained substance. Furthermore, distinct crystal forms display different physical properties such as melting points, hygroscopicities, solubilities, flow properties or thermodynamic stabilities, and, hence, distinct crystal forms allow the choice of the most suitable form for a certain use or aspect, e.g. the use as an intermediate in the process of drug manufacture or in distinct administration forms like tablets, capsules, ointments or solutions.
The δ-crystal form and the ε-crystal form of the methanesulfonic acid addition salt of a compound of formula I possesses valuable pharmacological properties and may, for example, be used as an anti-tumour agent or as an agent to treat restenosis.
The present invention relates especially to the δ-crystal form of the methanesulfonic acid addition salt of a compound of formula I in the treatment of one of the said diseases mentioned herein or in the preparation of a pharmacological agent for the treatment thereof.
Additionally, the present invention relates especially to the ε-crystal form of the methanesulfonic acid addition salt of a compound of formula I in the treatment of one of the said diseases mentioned herein or in the preparation of a pharmacological agent for the treatment thereof.
The antiproliferative, especially anti-tumour, activity of the methanesulfonic acid addition salt of a compound of formula I in vivo is, for example, described for the treatment of abl- dependent tumours in Nature Med. 2, 561-6 (1996).
The invention relates also to a method for the treatment of warm-blooded animals suffering from said diseases, especially leukemia, wherein a quantity of the δ-crystal form or of the ε- crystal form of the methanesulfonic acid addition salt of a compound of formula I which is effective against the disease concerned, especially a quantity with antiproliferative efficacy, is administered to warm-blooded animals in need of such treatment. The invention relates moreover to the use of the δ-crystal form or of the ε-crystal form of the methanesulfonic acid addition salt of a compound of formula I for the preparation of pharmaceutical compositions for use in treating the human or animal body, especially for the treatment of tumours, such as gliomas or prostate tumours.
In preferred embodiments, the present invention relates to the use in of the δ-crystal form or of the ε-crystal form of the methanesulfonic acid addition salt of a compound of formula I in the treatment of one of the disorders listed below: 1. metastatic, inoperable GIST, 2. advanced chronic myeloid leukemia,
3. newly diagnosed chronic myeloid leukemia,
4. pediatric Philadelphia chromosome-positive chronic myeloid leukemia,
5. Philadelphia chromosome-positive acute lymphocytic leukemia (ALL),
6. glioblastoma multiforme, preferably in combination with hydroxyurea,
7. dermatofibrosarcoma protuberans (DFSP),
8. hypereosinophilic sindrome (HES), and
9. chronic myelomonocytic leucemia (CMML).
Depending on species, age, individual condition, mode of administration, and the clinical picture in question, effective doses, for example daily doses of about 50-2500 mg, preferably 100-1000 mg, especially 250-800 mg, of lmatinib mesylate having the δ-crystal form or the ε-crystal form are administered to warm-blooded animals of about 70 kg bodyweight. Preferably, daily dosages of 400 mg or 600 mg are administered orally once daily, preferably together with a meal and a large glass of water (about 200 mL).
800 mg daily dosages are preferably administered in the form of 400 mg dosages twice daily together with food.
The δ-crystal form and the ε-crystal form described herein can be utilized to prepare stable pharmaceutical dosage forms. Hence, the invention relates also to pharmaceutical preparations which contain an amount, especially an effective amount for prevention or treatment of one of the diseases mentioned herein, of the methanesulfonic acid addition salt of a compound of formula I in the δ-crystal form or the ε-crystal form, together with pharmaceutically acceptable carriers which are suitable for topical, enteral, for example oral or rectal, or parenteral administration and may be inorganic or organic and solid or liquid. Especially tablets or gelatin capsules containing the active substance together with diluents, for example lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and/or glycerin, and/or lubricants, for example silica, talc, stearic acid, or salts thereof, typically magnesium or calcium stearate, and/or polyethylene glycol, are used for oral administration. Tablets may likewise contain binders, for example magnesium aluminium silicate, starches, typically corn, wheat or rice starch, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and, if so desired, disintegrants, for example starches, agar, alginic acid, or a salt thereof, typically sodium alginate, and/or effervescent mixtures, or adsorbents, colouring agents, flavours, and sweetening agents. The pharmacologically active compounds of the present invention may further be used in the form of preparations for parenteral administration or infusion solutions. Such solutions are preferably isotonic aqueous solutions or suspensions, these possibly being prepared before use, for example in the case of lyophilised preparations containing the active substance either alone or together with a carrier, for example mannitol. The pharmaceutical substances may be sterilised and/or may contain excipients, for example preservatives, stabilisers, wetting agents and/or emulsifiers, solubilisers, salts for the regulation of osmotic pressure, and/or buffers. The present pharmaceutical preparations which, if so desired, may contain further pharmacologically active substances, are prepared in a manner known per se, for example by means of conventional mixing, granulating, coating, dissolving or lyophilising processes, and contain from about 1 % to 100%, especially from about 1 % to about 20%, of the active substance or substances. In a preferred embodiment, the tablet or capsule contains 50 mg 100 mg of the of the methanesulfonic acid addition salt of a compound of formula I in the δ-crystal form, optionally together with pharmaceutically acceptable carriers.
In one embodiment, the capsule is a hard gelatine capsule containing a dry powder blend. The capsule shell preferably contains gelatine and titanium dioxide as well as red iron oxide. The ratio of weight of capsule fill to capsule shell is preferably between about 100:25 and 100:50, more preferably between 100:30 and 100:40.
In another embodiment, a film coated tablet is used comprising 100 mg, 400 mg or 800 mg drug substance together with inactive excepients selected from colloidal anhydrous silica, polyvinylpyrrolidone, magnesium stearate and microcrystalline cellulose.
The following Examples illustrate the invention without limiting the scope thereof. Temperatures are given in degrees Celsius (0C).
Examples
Example 1 : Preparation of crystalline form delta of lmatinib mesylate using acetone and methanol
About 500mg of lmatinib mesylate is first dissolved in about 100ml of water. A micro reactor is charged with about 50μl of this aqueous solution of lmatinib mesylate. The solution is flushed with nitrogen at room temperature to dry the solution. The dry precipitate is re- suspended with about 125μl amounts of each, acetone and methanol. The suspension is aged at about 45-55°C for about 2hrs. The solution is then allowed to evaporate at 45°C to 55°C under a stream of nitrogen.
Example 2: Tablets with lmatinib mesylate, δ-crvstal form
Tablets containing 100 mg of the active substance named in the title are usually prepared in the following composition:
Composition
Active ingredient 100 mg
Crystalline lactose 240 mg
Avicel 80 mg
PVPPXL 20 mg
Aerosil 2 mg
Magnesium stearate 5 mg
447 mg
Preparation: The active substance is mixed with carrier materials and compressed on a tableting machine (Korsch EKO, punch diameter 10 mm). Avicel is microcrystalline cellulose (FMC, Philadelphia, USA). PVPPXL is polyvinylpyrrolidone, cross-linked (BASF, Germany). Aerosil is silicon dioxide (Degussa, Germany).
Example 3: Capsules with lmatinib mesylate, δ-crvstal form
Capsules containing 100 mg of the compound named in the title as active substance are usually prepared in the following composition:
Composition
Active ingredient 100 mg
Avicel 200mg PVPPXL 15 mg
Aerosil 2 mg
Magnesium stearate 1.5 mg
318.5 mg
The capsules are prepared by mixing the components and filling the mixture into hard gelatin capsules, size 1.
Example 4: Preparation of crystalline form epsilon of lmatinib mesylate using ethyl acetate and ethanol
About 500mg of lmatinib mesylate drug substance is first dissolved in about 100ml of water. A micro reactor is charged with about 50μl of this aqueous solution of lmatinib mesylate. The solution is flushed with nitrogen at room temperature to dry the solution. The dry precipitate is resuspended with about 125μl amounts of each, ethyl acetate and 95% ethanol. The suspension is aged at about 45-55°C for about 2hrs. The solution is then allowed to evaporate at 45°C to 55°C under a stream of nitrogen.
Example 5: Tablets with lmatinib mesylate, ε-crvstal form
Tablets containing 100 mg of the active substance named in the title are usually prepared in the following composition:
Composition
Active ingredient 100 mg
Crystalline lactose 240 mg
Avicel 80 mg
PVPPXL 20 mg
Aerosil 2 mg
Magnesium stearate 5 mg
447 mg Preparation: The active substance is mixed with carrier materials and compressed on a tableting machine (Korsch EKO, punch diameter 10 mm). Avicel is microcrystalline cellulose (FMC, Philadelphia, USA). PVPPXL is polyvinylpolypyrrolidone, cross-linked (BASF, Germany). Aerosil is silicon dioxide (Degussa, Germany).
Example 6: Capsules with lmatinib mesylate, ε-crvstal form
Capsules containing 100 mg of the compound named in the title as active substance are usually prepared in the following composition:
Composition
Active ingredient 100 mg
Avicel 200mg
PVPPXL 15 mg
Aerosil 2 mg
Magnesium stearate 1.5 mg
318.5 mg
The capsules are prepared by mixing the components and filling the mixture into hard gelatin capsules, size 1.

Claims

What is claimed is:
1. Crystalline form delta of the methanesulfonic acid addition salt of a compound of formula I
Figure imgf000014_0001
2. The crystalline form according to claim 1 , which shows on X-ray diffraction peaks at an angle of refraction 2theta of (a) 7.8°, (b) 8.3° and (c) 9.0°.
3. The crystalline form according to claim 1 , which shows on X-ray diffraction peaks at an angle of refraction 2theta of (a) 19.2° and (b) 19.8°.
4. The crystalline form according to claim 1 or 2, which shows on X-ray diffraction peaks at an angle of refraction 2theta of (a) 19.2°, said peak having a relative line intensity of 70, (b) 19.8°, said peak having a relative line intensity of 100 and (c) 21.1 °, said peak having a relative line intensity of 69.
5. The crystalline form according to claim 1 , which shows in an X-ray diffraction diagram lines having a relative line intensity of 50 or more at the following angles of refraction 2theta (relative line intensities given in parentheses): 19.2° (70), 19.4° (51 ), 19.8° (100), 20.3° (60), 20.7° (52), 20.9° (65) and 21.1 ° (69).
6. The crystalline form according to claim 1 , which shows in an X-ray diffraction diagram lines having a relative line intensity of 40 or more at the following angles of refraction 2theta (relative line intensities given in parentheses): 16.5° (44), 16.8° (44), 19.2° (70), 19.4° (51 ), 19.8° (100), 20.3° (60), 20.7° (52), 20.9° (65), 21.1 ° (69) and 22.7° (41 ).
7. The crystalline form of the methanesulfonic acid addition salt of a compound of formula I according to any one of the claims 1 to 6, which is present in essentially pure form.
8. A crystalline form of the methanesulfonic acid addition salt of a compound of formula I
Figure imgf000015_0001
which shows an X-ray diffraction diagram of the type shown in Fig. 1 , in which the relative peak intensities of each peak do not deviate by more than 10% from the relative peak intensities in the diagram shown in Fig. 1.
9. Crystalline form epsilon of the methanesulfonic acid addition salt of a compound of formula I
Figure imgf000015_0002
10. The crystalline form according to claim 9, which shows on X-ray diffraction peaks at an angle of refraction 2theta of (a) 9.4° and (b) 28.2°.
11. The crystalline form according to claim 9, which shows on X-ray diffraction peaks at an angle of refraction 2theta of (a) 17.0°, (b) 18.5°, (c) 19.6° and (d) 20.7°.
12. The crystalline form according to claim 9 or 10 which shows on X-ray diffraction peaks at an angle of refraction 2theta of (a) 17.0°, said peak having a relative line intensity of 99, (b) 18.5°, said peak having a relative line intensity of 80, (c) 19.6°, said peak having a relative line intensity of 78 and (d) 20.7°, said peak having a relative line intensity of 100.
13. The crystalline form according to claim 9 or 10, which shows in an X-ray diffraction diagram lines having a relative line intensity of 50 or more at the following angles of refraction 2theta (relative line intensities given in parentheses): 13.9° (58), 17.0° (99), 17.9° (59), 18.5° (80), 19.6° (78), 20.7° (100) and 24.1 ° (62).
14. The crystalline form according to claim 9 or 10, which shows in an X-ray diffraction diagram lines having a relative line intensity of 40 or more at the following angles of refraction 2theta (relative line intensities given in parentheses): 12.7° (48), 13.9° (58), 17.0° (99), 17.9° (59), 18.5° (80), 19.6° (78), 20.7° (100), 21.4° (40), 23.6° (49), 24.1 ° (62) and 28.2° (45).
15. The crystalline form according to any one of the claims 9 to 14, which is present in essentially pure form.
16. A crystalline form of the methanesulfonic acid addition salt of a compound of formula I
Figure imgf000016_0001
which shows an X-ray diffraction diagram of the type shown in Fig. 2, in which the relative peak intensities of each peak do not deviate by more than 10% from the relative peak intensities in the diagram shown in Fig. 2.
17. A composition containing the methanesulfonic acid addition salt of a compound of formula I
Figure imgf000017_0001
comprising a crystalline form of the methanesulfonic acid addition salt of a compound of formula I according to any one of the claims 1 to 16.
18. The composition according to claim 17 comprising additionally at least one distinct form of the methanesulfonic acid addition salt of a compound of formula I selected from the amorphous form, the α-crystal form, the β-crystal form and the H 1 -crystal form.
19. A pharmaceutical composition comprising a crystalline form of the methanesulfonic acid addition salt of a compound of formula I according to any one of the claims 1 to 16, and optionally at least one pharmaceutically acceptable carrier.
20. The pharmaceutical composition according to claim 19 comprising additionally at least one distinct form of the methanesulfonic acid addition salt of a compound of formula I selected from the amorphous form, the α-crystal form, the β-crystal form and the H1- crystal form.
21. The pharmaceutical composition according to claim 19 or 20 comprising between 50 mg and 800 mg of a crystalline form of the methanesulfonic acid addition salt of a compound of formula I according to any one of the claims 1 to 16.
22. The pharmaceutical composition according to any one of claims 19 to 21 which is a capsule containing a dry powder blend comprising between 50 mg and 200 mg of a crystalline form of the methanesulfonic acid addition salt of a compound of formula I according to any one of the claims 1 to 16.
23. The capsule according to claim 22, wherein the shell contains gelatine.
24. The capsule according to claim 22, wherein the shell contains titanium dioxide.
25. The capsule according to claim 22, wherein the shell contains red iron oxide.
26. The capsule according to claim 22, wherein the ratio of weight of capsule fill to capsule shell is between about 100:25 and 100:50.
27. The capsule according to claim 22, wherein the ratio of weight of capsule fill to capsule shell is between 100:30 and 100:40.
28. The pharmaceutical composition according to any one of claims 19 to 21 which is a tablet comprising 100 mg, 400 mg or 800 mg drug substance together with inactive excepients.
29. The tablet according to claim 28 wherein the inactive excepients are selected from colloidal anhydrous silica, polyvinylpyrrolidone, magnesium stearate and microcrystalline cellulose.
30. The use of a crystalline form of the methanesulfonic acid addition salt of a compound of formula I according to any one of the claims 1 to 16 for the preparation of a medicament for the treatment of a disease selected from metastatic, inoperable GIST, advanced chronic myeloid leukemia, newly diagnosed chronic myeloid leukemia, pediatric Philadelphia chromosome-positive chronic myeloid leukemia, Philadelphia chromosome- positive acute lymphocytic leukemia (ALL), glioblastoma multiforme, dermatofibrosarcoma protuberans (DFSP), hypereosinophilic sindrome (HES), and chronic myelomonocytic leucemia (CMML).
31. Method of treating a disease selected from metastatic, inoperable GIST, advanced chronic myeloid leukemia, newly diagnosed chronic myeloid leukemia, pediatric Philadelphia chromosome-positive chronic myeloid leukemia, Philadelphia chromosome- positive acute lymphocytic leukemia (ALL), glioblastoma multiforme, dermatofibrosarcoma protuberans (DFSP), hypereosinophilic sindrome (HES), and chronic myelomonocytic leucemia (CMML in a warm-blooded animal in need thereof comprising administering to the animal a crystalline form of the methanesulfonic acid addition salt of a compound of formula I according to any one of the claims 1 to 16 in a quantity which is therapeutically effective against the respective disease.
32. The method according to claim 31 , wherein a daily dosages of 400 mg or 600 mg is administered orally to the patient.
33. The method according to claim 32, wherein the total daily dosage is administered once daily with a meal and a large glass of water of about 200 ml_.
34. The method according to claim 31 , wherein a daily dosages of 800 mg is administered orally to the patient.
35. The method according to claim 34, wherein the total daily dosage is administered as 400 mg doses twice daily together with food.
PCT/EP2006/065662 2005-08-26 2006-08-24 Delta and epsilon crystal forms of imatinib mesylate WO2007023182A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP06792999A EP1922314A1 (en) 2005-08-26 2006-08-24 Delta and epsilon crystal forms of imatinib mesylate
AU2006283842A AU2006283842B2 (en) 2005-08-26 2006-08-24 Delta and epsilon crystal forms of imatinib mesylate
JP2008527470A JP2009506014A (en) 2005-08-26 2006-08-24 Delta and epsilon crystal forms of imatinib mesylate
CA002620835A CA2620835A1 (en) 2005-08-26 2006-08-24 Delta and epsilon crystal forms of imatinib mesylate
MX2008002541A MX2008002541A (en) 2005-08-26 2006-08-24 Delta and epsilon crystal forms of imatinib mesylate.
CN200680030515XA CN101243066B (en) 2005-08-26 2006-08-24 Delta and epsilon crystal forms of imatinib mesylate
BRPI0615383-6A BRPI0615383A2 (en) 2005-08-26 2006-08-24 delta and epsilon crystal forms of imatinib mesylate
US12/064,637 US7879860B2 (en) 2005-08-26 2006-08-24 Delta and epsilon crystal forms of Imatinib mesylate
IL189353A IL189353A (en) 2005-08-26 2008-02-07 Delta and epsilon crystal forms of imatinib mesylate, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for therapy
NO20081482A NO20081482L (en) 2005-08-26 2008-03-26 Delta and epsilon crystal forms for imatinib mesylate

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US71173705P 2005-08-26 2005-08-26
US71173805P 2005-08-26 2005-08-26
US60/711,738 2005-08-26
US60/711,737 2005-08-26
US71220605P 2005-08-29 2005-08-29
US60/712,206 2005-08-29

Publications (1)

Publication Number Publication Date
WO2007023182A1 true WO2007023182A1 (en) 2007-03-01

Family

ID=37192362

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/065662 WO2007023182A1 (en) 2005-08-26 2006-08-24 Delta and epsilon crystal forms of imatinib mesylate

Country Status (16)

Country Link
US (1) US7879860B2 (en)
EP (1) EP1922314A1 (en)
JP (1) JP2009506014A (en)
KR (1) KR20080049766A (en)
CN (2) CN102002035B (en)
AR (1) AR055613A1 (en)
AU (1) AU2006283842B2 (en)
BR (1) BRPI0615383A2 (en)
CA (1) CA2620835A1 (en)
EC (1) ECSP088217A (en)
IL (1) IL189353A (en)
MX (1) MX2008002541A (en)
MY (1) MY148375A (en)
NO (1) NO20081482L (en)
UY (1) UY29766A1 (en)
WO (1) WO2007023182A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059963A1 (en) * 2005-11-25 2007-05-31 Novartis Ag F,g,h,i and k crystal forms of imatinib mesylate
EP1988089A1 (en) 2006-10-26 2008-11-05 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
WO2008150481A3 (en) * 2007-05-29 2009-01-29 Sicor Inc Processes for the preparation of crystalline form beta of imatinib mesylate
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
WO2010133976A2 (en) 2009-05-22 2010-11-25 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
JP2010540465A (en) * 2007-09-25 2010-12-24 テバ ファーマシューティカル インダストリーズ リミティド Stable imatinib composition
WO2011023146A1 (en) 2009-08-26 2011-03-03 Zentiva, K.S. Imatinib mesylate polymorphs generated by crystallization in aqueous inorganic salt solutions
EP2311821A1 (en) 2006-04-27 2011-04-20 Sicor, Inc. Polymorphic form of Imatinib mesylate and processes for its preparation
WO2011049474A1 (en) 2009-10-22 2011-04-28 Tomasz Kozluk Salts of imatinib with tartaric acids
US7947699B2 (en) 2008-01-10 2011-05-24 Actavis Group Ptc Ehf Anhydrous amorphous imatinib mesylate
US7977348B2 (en) 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
WO2011095835A1 (en) 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Highly pure imatinib or a pharmaceutically acceptable salt thereof
WO2011099039A1 (en) 2010-02-15 2011-08-18 Reliance Life Sciences Pvt. Ltd. Process for the preparation of alpha form of imatinib mesylate
WO2011108953A1 (en) 2010-03-04 2011-09-09 Tomasz Kozluk PROCESS FOR PREPARATION OF POLYMORPHIC FORM α AND NEW POLYMORPHIC FORM OF IMATINIB MESYLATE ISOLATED IN THAT PROCESS
US8067421B2 (en) 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
WO2011157450A1 (en) 2010-06-18 2011-12-22 Krka, D. D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
WO2012071980A1 (en) 2010-11-30 2012-06-07 浙江九洲药业股份有限公司 Preparation method of α-imatinib mesylate
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
EP2497464A2 (en) 2011-03-09 2012-09-12 Adamed SP. Z O.O. Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture
EP2604596A1 (en) * 2011-12-16 2013-06-19 Deva Holding Anonim Sirketi Polymorphs of imatinib
WO2013189910A1 (en) 2012-06-22 2013-12-27 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
EP2803352A1 (en) 2013-05-14 2014-11-19 Hetero Research Foundation High dose imatinib tablets
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib
WO2017129624A1 (en) 2016-01-25 2017-08-03 Krka, D.D., Novo Mesto Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5928159B2 (en) * 2012-05-28 2016-06-01 ニプロ株式会社 Pharmaceutical composition
CN103570676B (en) * 2012-08-04 2016-03-16 正大天晴药业集团股份有限公司 The preparation of imatinib mesylate α crystallization and pharmaceutical composition thereof
PL3539138T3 (en) 2016-11-11 2021-12-13 Curium Us Llc Processes for generating germanium-68 with reduced volatiles
CN112851640B (en) * 2019-11-28 2023-09-01 广东东阳光药业股份有限公司 Sulfate of pyrimidine benzamide compound and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003854A1 (en) * 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
WO2004106326A1 (en) * 2003-06-02 2004-12-09 Hetero Drugs Limited Novel polymorphs of imatinib mesylate
WO2005077933A1 (en) * 2004-02-11 2005-08-25 Natco Pharma Limited Novel polymorphic form of imatinib mesylate and a process for its preparation
WO2005095379A2 (en) * 2004-04-02 2005-10-13 Instytut Farmaceutyczny Crystalline methanesulfonic acid addition salts of imatinib
WO2006024863A1 (en) * 2004-09-02 2006-03-09 Cipla Limited Stable crystal form of imatinib mesylate and process for the preparation thereof
WO2006048890A1 (en) * 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Imatinib mesylate crystal form and process for preparation thereof
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003854A1 (en) * 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
WO2004106326A1 (en) * 2003-06-02 2004-12-09 Hetero Drugs Limited Novel polymorphs of imatinib mesylate
WO2005077933A1 (en) * 2004-02-11 2005-08-25 Natco Pharma Limited Novel polymorphic form of imatinib mesylate and a process for its preparation
WO2005095379A2 (en) * 2004-04-02 2005-10-13 Instytut Farmaceutyczny Crystalline methanesulfonic acid addition salts of imatinib
WO2006024863A1 (en) * 2004-09-02 2006-03-09 Cipla Limited Stable crystal form of imatinib mesylate and process for the preparation thereof
WO2006048890A1 (en) * 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Imatinib mesylate crystal form and process for preparation thereof
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059963A1 (en) * 2005-11-25 2007-05-31 Novartis Ag F,g,h,i and k crystal forms of imatinib mesylate
US8846706B2 (en) 2005-11-25 2014-09-30 Novartis Ag Crystalline form K of imatinib mesylate
US8633213B2 (en) 2005-11-25 2014-01-21 Novartis Ag Crystalline form F of imatinib mesylate
US8592440B2 (en) 2005-11-25 2013-11-26 Novartis Ag Crystalline form I of imatinib mesylate
US8507515B2 (en) 2005-11-25 2013-08-13 Novartis Ag Crystalline form G of imatinib mesylate
EP2578580A1 (en) * 2005-11-25 2013-04-10 Novartis AG G, I and K crystal forms of imatinib mesylate
EP2546248A1 (en) * 2005-11-25 2013-01-16 Novartis AG Crystal form H of imatinib mesylate
US7893076B2 (en) 2005-11-25 2011-02-22 Novartis Ag Crystalline form F of Imatinib mesylate
US8198289B2 (en) 2005-11-25 2012-06-12 Novartis Ag Crystal form H imatinib mesylate for pharmaceutical use
EP2311821A1 (en) 2006-04-27 2011-04-20 Sicor, Inc. Polymorphic form of Imatinib mesylate and processes for its preparation
EP2829538A1 (en) 2006-04-27 2015-01-28 Sicor, Inc. Polymorphic form of imatinib mesylate and process for its preparation
US7977348B2 (en) 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US8067421B2 (en) 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
EP1988089A1 (en) 2006-10-26 2008-11-05 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
EP2009008A1 (en) 2006-10-26 2008-12-31 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
WO2008150481A3 (en) * 2007-05-29 2009-01-29 Sicor Inc Processes for the preparation of crystalline form beta of imatinib mesylate
JP2010540465A (en) * 2007-09-25 2010-12-24 テバ ファーマシューティカル インダストリーズ リミティド Stable imatinib composition
US8414918B2 (en) 2007-09-25 2013-04-09 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
US7947699B2 (en) 2008-01-10 2011-05-24 Actavis Group Ptc Ehf Anhydrous amorphous imatinib mesylate
WO2010133976A2 (en) 2009-05-22 2010-11-25 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
WO2011023146A1 (en) 2009-08-26 2011-03-03 Zentiva, K.S. Imatinib mesylate polymorphs generated by crystallization in aqueous inorganic salt solutions
WO2011049474A1 (en) 2009-10-22 2011-04-28 Tomasz Kozluk Salts of imatinib with tartaric acids
WO2011095835A1 (en) 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Highly pure imatinib or a pharmaceutically acceptable salt thereof
WO2011099039A1 (en) 2010-02-15 2011-08-18 Reliance Life Sciences Pvt. Ltd. Process for the preparation of alpha form of imatinib mesylate
WO2011108953A1 (en) 2010-03-04 2011-09-09 Tomasz Kozluk PROCESS FOR PREPARATION OF POLYMORPHIC FORM α AND NEW POLYMORPHIC FORM OF IMATINIB MESYLATE ISOLATED IN THAT PROCESS
WO2011157450A1 (en) 2010-06-18 2011-12-22 Krka, D. D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
WO2012071980A1 (en) 2010-11-30 2012-06-07 浙江九洲药业股份有限公司 Preparation method of α-imatinib mesylate
US8871930B2 (en) 2010-11-30 2014-10-28 Zhejiang Jiuzhou Pharma Science & Technology Co., Ltd. Preparation method of alpha-imatinib mesylate
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
EP2497464A2 (en) 2011-03-09 2012-09-12 Adamed SP. Z O.O. Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture
EP2604596A1 (en) * 2011-12-16 2013-06-19 Deva Holding Anonim Sirketi Polymorphs of imatinib
WO2013189910A1 (en) 2012-06-22 2013-12-27 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
US9221789B2 (en) 2012-06-22 2015-12-29 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
EP2803352A1 (en) 2013-05-14 2014-11-19 Hetero Research Foundation High dose imatinib tablets
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib
WO2017129624A1 (en) 2016-01-25 2017-08-03 Krka, D.D., Novo Mesto Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor

Also Published As

Publication number Publication date
AU2006283842A1 (en) 2007-03-01
CN102002035A (en) 2011-04-06
MX2008002541A (en) 2008-03-14
US7879860B2 (en) 2011-02-01
US20080254116A1 (en) 2008-10-16
ECSP088217A (en) 2008-03-26
JP2009506014A (en) 2009-02-12
AU2006283842B2 (en) 2011-03-17
UY29766A1 (en) 2007-03-30
CN102002035B (en) 2013-02-27
NO20081482L (en) 2008-05-16
AR055613A1 (en) 2007-08-29
KR20080049766A (en) 2008-06-04
IL189353A (en) 2014-12-31
CA2620835A1 (en) 2007-03-01
MY148375A (en) 2013-04-15
CN101243066B (en) 2012-11-14
IL189353A0 (en) 2008-06-05
EP1922314A1 (en) 2008-05-21
BRPI0615383A2 (en) 2011-05-17
CN101243066A (en) 2008-08-13

Similar Documents

Publication Publication Date Title
US7879860B2 (en) Delta and epsilon crystal forms of Imatinib mesylate
CA2628330C (en) F,g,h,i and k crystal forms of imatinib mesylate
HK1177737A (en) Crystal form h of imatinib mesylate
MX2008006696A (en) F,g,h,i and k crystal forms of imatinib mesylate
CN101312960A (en) F,G,H,I and K crystal forms of imatinib mesylate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006792999

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 189353

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006283842

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200680030515.X

Country of ref document: CN

Ref document number: 1518/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/002541

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12064637

Country of ref document: US

Ref document number: 2008527470

Country of ref document: JP

Ref document number: 2620835

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006283842

Country of ref document: AU

Date of ref document: 20060824

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006283842

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020087007150

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008111064

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2006792999

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0615383

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080227